These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33558080)

  • 21. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
    Ohto U; Usui K; Ochi T; Yuki K; Satow Y; Shimizu T
    J Biol Chem; 2012 Jan; 287(3):1801-12. PubMed ID: 22128166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and molecular characteristics of 11 Chinese probands with GM1 gangliosidosis.
    Feng Y; Huang Y; Zhao X; Sheng H; Feng Y; Zhang W; Liu L
    Metab Brain Dis; 2018 Dec; 33(6):2051-2057. PubMed ID: 30267299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.
    Okumiya T; Sakuraba H; Kase R; Sugiura T
    Mol Genet Metab; 2003 Jan; 78(1):51-8. PubMed ID: 12559848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis.
    Sperb F; Vairo F; Burin M; Mayer FQ; Matte U; Giugliani R
    Gene; 2013 Jan; 512(1):113-6. PubMed ID: 23046582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
    Front S; Biela-Banaś A; Burda P; Ballhausen D; Higaki K; Caciotti A; Morrone A; Charollais-Thoenig J; Gallienne E; Demotz S; Martin OR
    Eur J Med Chem; 2017 Jan; 126():160-170. PubMed ID: 27750150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [beta-Galactosidosis (acid beta-galactosidase deficiency: GM1 gangliosidosis, Morquio B disease)].
    Nishigaki T; Okada S
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):403-6. PubMed ID: 9645093
    [No Abstract]   [Full Text] [Related]  

  • 27. beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement.
    Morrone A; Bardelli T; Donati MA; Giorgi M; Di Rocco M; Gatti R; Parini R; Ricci R; Taddeucci G; D'Azzo A; Zammarchi E
    Hum Mutat; 2000; 15(4):354-66. PubMed ID: 10737981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene.
    Karimzadeh P; Naderi S; Modarresi F; Dastsooz H; Nemati H; Farokhashtiani T; Shamsian BS; Inaloo S; Faghihi MA
    BMC Med Genet; 2017 Jul; 18(1):73. PubMed ID: 28716012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mongolian spots in GM1 gangliosidosis: a pictorial report.
    Mishra S; Pai P; Uttarilli A; Girisha KM
    Clin Dysmorphol; 2021 Jan; 30(1):6-9. PubMed ID: 33038107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.
    Fantur KM; Wrodnigg TM; Stütz AE; Pabst BM; Paschke E
    J Inherit Metab Dis; 2012 May; 35(3):495-503. PubMed ID: 22033734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Processing of human beta-galactosidase in GM1-gangliosidosis and Morquio B syndrome.
    Hoogeveen AT; Graham-Kawashima H; d'Azzo A; Galjaard H
    J Biol Chem; 1984 Feb; 259(3):1974-7. PubMed ID: 6420416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [GLB1 gene mutation and clinical characteristics of a patient with mucopolysaccharidosis type IVB].
    Lei HL; Ye J; Qiu WJ; Zhang HW; Han LS; Gu XF
    Zhonghua Er Ke Za Zhi; 2012 Jul; 50(7):549-53. PubMed ID: 22932019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent and novel GLB1 mutations in India.
    Bidchol AM; Dalal A; Trivedi R; Shukla A; Nampoothiri S; Sankar VH; Danda S; Gupta N; Kabra M; Hebbar SA; Bhat RY; Matta D; Ekbote AV; Puri RD; Phadke SR; Gowrishankar K; Aggarwal S; Ranganath P; Sharda S; Kamate M; Datar CA; Bhat K; Kamath N; Shah H; Krishna S; Gopinath PM; Verma IC; Nagarajaram HA; Satyamoorthy K; Girisha KM
    Gene; 2015 Aug; 567(2):173-81. PubMed ID: 25936995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein modeling and clinical description of a novel in-frame GLB1 deletion causing GM1 gangliosidosis type II.
    Richter JE; Zimmermann MT; Blackburn PR; Mohammad AN; Klee EW; Pollard LM; Macmurdo CF; Atwal PS; Caulfield TR
    Mol Genet Genomic Med; 2018 Nov; 6(6):1229-1235. PubMed ID: 30187681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct
    Stockler-Ipsiroglu S; Yazdanpanah N; Yazdanpanah M; Moisa Popurs M; Yuskiv N; Schmitz Ferreira Santos ML; Ae Kim C; Fischinger Moura de Souza C; Marques Lourenço C; Steiner CE; Federhen A; Giugliani L; Bastos Pereira DM; Durán-Carabali LE; Giugliani R
    JIMD Rep; 2021 Jul; 60(1):23-31. PubMed ID: 34258138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disentangling molecular and clinical stratification patterns in beta-galactosidase deficiency.
    Tebani A; Sudrié-Arnaud B; Dabaj I; Torre S; Domitille L; Snanoudj S; Heron B; Levade T; Caillaud C; Vergnaud S; Saugier-Veber P; Coutant S; Dranguet H; Froissart R; Al Khouri M; Alembik Y; Baruteau J; Arnoux JB; Brassier A; Brehin AC; Busa T; Cano A; Chabrol B; Coubes C; Desguerre I; Doco-Fenzy M; Drenou B; Elcioglu NH; Elsayed S; Fouilhoux A; Poirsier C; Goldenberg A; Jouvencel P; Kuster A; Labarthe F; Lazaro L; Pichard S; Rivera S; Roche S; Roggerone S; Roubertie A; Sigaudy S; Spodenkiewicz M; Tardieu M; Vanhulle C; Marret S; Bekri S
    J Med Genet; 2022 Apr; 59(4):377-384. PubMed ID: 33737400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural bases of GM1 gangliosidosis and Morquio B disease.
    Morita M; Saito S; Ikeda K; Ohno K; Sugawara K; Suzuki T; Togawa T; Sakuraba H
    J Hum Genet; 2009 Sep; 54(9):510-5. PubMed ID: 19644515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.
    Higaki K; Li L; Bahrudin U; Okuzawa S; Takamuram A; Yamamoto K; Adachi K; Paraguison RC; Takai T; Ikehata H; Tominaga L; Hisatome I; Iida M; Ogawa S; Matsuda J; Ninomiya H; Sakakibara Y; Ohno K; Suzuki Y; Nanba E
    Hum Mutat; 2011 Jul; 32(7):843-52. PubMed ID: 21520340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases.
    Ou L; Przybilla MJ; Whitley CB
    Clin Genet; 2018 May; 93(5):1008-1014. PubMed ID: 29396849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Arg482His mutation in the beta-galactosidase gene is responsible for a high frequency of GM1 gangliosidosis carriers in a Cypriot village.
    Georgiou T; Stylianidou G; Anastasiadou V; Caciotti A; Campos Y; Zammarchi E; Morrone A; D'azzo A; Drousiotou A
    Genet Test; 2005; 9(2):126-32. PubMed ID: 15943552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.